Golimumab

Golimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TNFα
Clinical data
Trade names Simponi
AHFS/Drugs.com monograph
MedlinePlus a610010
License data
Routes of
administration		 Subcutaneous injection
Legal status
Legal status
Identifiers
CAS Number 476181-74-5 N
ATC code L04AB06 (WHO)
ChemSpider none
UNII 91X1KLU43E YesY
KEGG D04358 YesY
ChEMBL CHEMBL1201833 N
Chemical data
Formula C6530H10068N1752O2026S44
Molar mass 147 kg/mol
 NYesY (what is this?)  (verify)

Golimumab (CNTO 148)[1] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[2] and hence is a TNF inhibitor.

Golimumab was developed by Centocor and is approved in Canada[3] and the United States[4] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[5][6] Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis.

In the same year, Johnson & Johnson, the parent company of Centocor, also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[7] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[8][9][10]

Clinical trials

Rheumatoid arthritis

Large, double-blind randomized controlled trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[11]

References

  1. ↑ Mazumdar, Sohini; David Greenwald (2009). "Golimumab". mAbs 1 (5): 422–431. doi:10.4161/mabs.1.5.9286.
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab, American Medical Association.
  3. ↑ "Health Canada Approves Simponi (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis". Apr 2009
  4. ↑ FDA Approves Simponi
  5. ↑ "FDA clears potential blockbuster arthritis drug". North County Times (Lee Enterprises). Associated Press. 24 April 2009. Retrieved 23 October 2010.
  6. ↑ Maxwell, LJ; Zochling, J; Boonen, A; Singh, JA; Veras, MM; Tanjong Ghogomu, E; Benkhalti Jandu, M; Tugwell, P; Wells, GA (18 April 2015). "TNF-alpha inhibitors for ankylosing spondylitis.". The Cochrane database of systematic reviews 4: CD005468. PMID 25887212.
  7. ↑ Johnson & Johnson Reports 2008 First-Quarter Results
  8. ↑ FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab
  9. ↑ Merck sees fast ruling in J&J Remicade arbitration
  10. ↑ "Simponi European Public Assessment Report". European Medicines Agency. Retrieved 2009-11-15.
  11. ↑ Oldfield V, Plosker GL..Biodrugs 2009;23(2):125-135. doi:10.2165/00063030-200923020-00005.
This article is issued from Wikipedia - version of the Sunday, March 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.